Loading...
Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL‐2 inhibitor, in patients with non‐Hodgkin lymphoma
AIMS: To examine the effect of a strong cytochrome P450 (CYP) 3A inhibitor, ketoconazole, on the pharmacokinetics, safety and tolerability of venetoclax. METHODS: Twelve patients with non‐Hodgkin lymphoma (NHL) were enrolled in this Phase 1, open‐label, fixed‐sequence study. Patients received a sing...
Na minha lista:
| Udgivet i: | Br J Clin Pharmacol |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5346863/ https://ncbi.nlm.nih.gov/pubmed/27859472 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13175 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|